Patent · US Active

Epitope/peptide recognized by HLA-A2402-restricted Ep-CAM-specific CTL and use of the same

US7846651B2 · kind B2 · utility

3Cited by
2References
8Claims
0Family size

Assignees

Inventor

Key dates

Filing dateSep 22, 2009
Grant dateDec 7, 2010
Priority date—
Expiry dateSep 22, 2029

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K39/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:1; a peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:2; or a mutant peptide consisting essentially of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 or 2 by addition, deletion or substitution of one or more amino acids, the peptide being capable of forming a complex with an HLA-A2402 molecule to be recognized by HLA-A2402-restricted cytotoxic T lymphocytes or induce such lymphocytes. Such a peptide is useful as a cancer vaccine for epithelial cancer patients having HLA-A2402.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.